|
業務類別
|
Biotechnology |
|
業務概覽
|
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal sprayto be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |
| 公司地址
| 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6 |
| 電話號碼
| +1 514 336-0444 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.milestonepharma.com |
| 員工數量
| 33 |
| Mr. Joseph G. Oliveto |
Director, President and Chief Executive Officer |
美元 601.52K |
30/04/2025 |
| Mr. Lorenz Muller |
Chief Commercial Officer |
-- |
30/04/2025 |
| Mr. Jeffrey Edward Nelson |
Chief Operating Officer |
-- |
30/04/2025 |
| Mr. Amit Hasija |
Chief Financial Officer, Principal Accounting Officer and Executive Vice President, Corporate Development |
美元 437.75K |
30/04/2025 |
| Dr. David Bharucha, M.D.,PhD |
Chief Medical Officer |
美元 458.35K |
30/04/2025 |
|
|
| Mr. Joseph G. Oliveto |
Director, President and Chief Executive Officer |
30/04/2025 |
| Mr. Andrew R. Saik |
Independent Director |
30/04/2025 |
| Ms. Lisa M. Giles |
Independent Director |
30/04/2025 |
| Mr. Michael J. Tomsicek, M.B.A. |
Independent Director |
30/04/2025 |
| Mr. Joseph C. Papa, M.B.A.,R.Ph. |
Director |
30/04/2025 |
| Dr. Robert J. Wills, PhD |
Chairman of the Board |
30/04/2025 |
| Mr. Stuart M. Duty |
Independent Director |
30/04/2025 |
| Mr. Seth H.Z. Fischer |
Independent Director |
30/04/2025 |
|
|
|
|
